390 related articles for article (PubMed ID: 34580767)
1. Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes.
Stanton AM; Vaduganathan M; Chang LS; Turchin A; Januzzi JL; Aroda VR
Curr Diab Rep; 2021 Sep; 21(10):41. PubMed ID: 34580767
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center.
Swiatkiewicz I; Patel NT; Villarreal-Gonzalez M; Taub PR
BMC Med; 2024 May; 22(1):195. PubMed ID: 38745169
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.
Segar MW; Khan MS; Patel KV; Butler J; Tang WHW; Vaduganathan M; Lam CSP; Verma S; McGuire DK; Pandey A
J Am Coll Cardiol; 2021 Oct; 78(16):1587-1598. PubMed ID: 34649696
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.
Januzzi JL; Butler J; Del Prato S; Ezekowitz JA; Ibrahim NE; Lam CSP; Lewis GD; Marwick TH; Rosenstock J; Tang WHW; Zannad F; Lawson F; Perfetti R; Urbinati A
Am Heart J; 2023 Feb; 256():25-36. PubMed ID: 36372245
[TBL] [Abstract][Full Text] [Related]
5. Redefining Diabetic Cardiomyopathy: Perturbations in Substrate Metabolism at the Heart of Its Pathology.
Heather LC; Gopal K; Srnic N; Ussher JR
Diabetes; 2024 May; 73(5):659-670. PubMed ID: 38387045
[TBL] [Abstract][Full Text] [Related]
6. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
Januzzi JL; Del Prato S; Rosenstock J; Butler J; Ezekowitz J; Ibrahim NE; Lam CSP; Marwick T; Wilson Tang WH; Liu Y; Mohebi R; Urbinati A; Zannad F; Perfetti R
Cardiovasc Diabetol; 2024 Feb; 23(1):49. PubMed ID: 38302936
[TBL] [Abstract][Full Text] [Related]
7. Serum Annexin A2 concentrations are increased in patients with diabetic cardiomyopathy and are linked to cardiac dysfunctions.
He Q; Zhu J; Yang G; Liu X; Li L; Wang Y; Xiong X; Zheng Y; Zheng H; Qu H
Diabetes Res Clin Pract; 2023 Jan; 195():110196. PubMed ID: 36464090
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Predictors of Subclinical Cardiomyopathy in Patients With Type 2 Diabetes in a Health System.
Nagori A; Segar MW; Keshvani N; Patel L; Patel KV; Chandra A; Willett D; Pandey A
J Diabetes Sci Technol; 2023 Dec; ():19322968231212219. PubMed ID: 38063209
[TBL] [Abstract][Full Text] [Related]
9. Current Role of Dapagliflozin in Clinical Practice.
Zargar AH; Trailokya AA; Ghag S; Pawar R; Aiwale A; Zalke A
J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585897
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical value of fibrinogen-like protein 1 as a serum biomarker for the identification of diabetic cardiomyopathy.
Liu Y; Wang M; Su JB; Fu X; Zheng GL; Guo S; Zhang LJ; Lu QB
Sci Rep; 2024 May; 14(1):10311. PubMed ID: 38705920
[TBL] [Abstract][Full Text] [Related]
11. An Insight into the Pathogenesis of Diabetic Cardiomyopathy Along with the Novel Potential Therapeutic Approaches.
Vig H; Ravinandan AP; Vishwas HN; Tyagi S; Rathore S; Wal A; Wal P
Curr Diabetes Rev; 2024; 20(1):e020523216416. PubMed ID: 37138437
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.
Prandi FR; Evangelista I; Sergi D; Palazzuoli A; Romeo F
Heart Fail Rev; 2023 May; 28(3):597-606. PubMed ID: 35001338
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy.
Byrne NJ; Rajasekaran NS; Abel ED; Bugger H
Free Radic Biol Med; 2021 Jun; 169():317-342. PubMed ID: 33910093
[TBL] [Abstract][Full Text] [Related]
14. Heart failure and diabetes: Clinical significance and epidemiology of this two-way association.
Jerkins T; McGill JB; Bell DSH
Diabetes Obes Metab; 2023 Jul; 25 Suppl 3():3-14. PubMed ID: 36949650
[TBL] [Abstract][Full Text] [Related]
15. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
Garla VV; Butler J; Lien LF
Curr Cardiol Rep; 2021 May; 23(6):59. PubMed ID: 33961133
[TBL] [Abstract][Full Text] [Related]
16. The impact of diabetes on heart failure development: The cardio-renal-metabolic connection.
Valensi P; Prévost G; Pinto S; Halimi JM; Donal E
Diabetes Res Clin Pract; 2021 May; 175():108831. PubMed ID: 33895192
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies.
Ghosh N; Chacko L; Bhattacharya H; Vallamkondu J; Nag S; Dey A; Karmakar T; Reddy PH; Kandimalla R; Dewanjee S
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189744
[TBL] [Abstract][Full Text] [Related]
18. Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes.
Malik ME; Andersson C; Blanche P; D'Souza M; Madelaire C; Zareini B; Lamberts M; Kristensen SL; Sattar N; McMurray J; Køber L; Torp-Pedersen C; Gislason G; Schou M
Clin Res Cardiol; 2023 Feb; 112(2):215-226. PubMed ID: 35396632
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
Reid T
J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
[TBL] [Abstract][Full Text] [Related]
20. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence.
Salvatore T; Galiero R; Caturano A; Vetrano E; Rinaldi L; Coviello F; Di Martino A; Albanese G; Marfella R; Sardu C; Sasso FC
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
